BMS won the nullity trial for the Baraclude’s patent

Published: 2015-01-15 13:30:34

Updated: 2015-01-15 13:30:34

BMS Pharmaceutical Korea announced on the 13^th that it won a nullity trial for the substance patent of the hepatitis type B treatment ‘Baraclude (generic name: entecavir)’.

Eun-young Kim, CEO of BMS Pharmaceutical Korea, stated “We welcome the reasonable decision of the patent judge who againclarified validity and effectiveness of the Baraclude’s substance patent.”

Baraclude is the hepatitis ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.